KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation ExpenseEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Issued
Ratios

Pacific Biosciences Of California (PACB) Receivables - Net (2016 - 2025)

Pacific Biosciences Of California has reported Receivables - Net over the past 16 years, most recently at $35.4 million for Q4 2025.

  • Quarterly results put Receivables - Net at $35.4 million for Q4 2025, up 28.79% from a year ago — trailing twelve months through Dec 2025 was $35.4 million (up 28.79% YoY), and the annual figure for FY2025 was $35.4 million, up 28.79%.
  • Receivables - Net for Q4 2025 was $35.4 million at Pacific Biosciences Of California, up from $30.6 million in the prior quarter.
  • Over the last five years, Receivables - Net for PACB hit a ceiling of $36.6 million in Q4 2023 and a floor of $12.9 million in Q1 2021.
  • Median Receivables - Net over the past 5 years was $29.4 million (2024), compared with a mean of $27.6 million.
  • Biggest five-year swings in Receivables - Net: soared 115.81% in 2022 and later decreased 24.83% in 2024.
  • Pacific Biosciences Of California's Receivables - Net stood at $24.2 million in 2021, then decreased by 22.5% to $18.8 million in 2022, then soared by 94.91% to $36.6 million in 2023, then dropped by 24.83% to $27.5 million in 2024, then increased by 28.79% to $35.4 million in 2025.
  • The last three reported values for Receivables - Net were $35.4 million (Q4 2025), $30.6 million (Q3 2025), and $32.3 million (Q2 2025) per Business Quant data.